Prot #SPI-ZEV-11-301: A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age with Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Rem

Project: Research project

Project Details

StatusFinished
Effective start/end date1/14/14 → 10/30/14

Funding

  • Spectrum Pharmaceuticals, Inc. (Prot #SPI-ZEV-11-301)